Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells

International Journal of Oncology

Volumn 51, Issue 6, 2017, Pages 1747-1756

  Rousseau, Aurélie ^a,b   Larsen, Annette K ^a   Van Dreden, Patrick ^b   Sabbah, Michele ^a   Elalamy, Ismail ^a,c   Gerotziafas, Grigoris T ^a,c  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b Clinical Research Department   (France)

^c HÔPITAL TENON   (France)

Author keywords

Cancer; Factor XII; Hypercoagulability; Thrombin Generation; Tissue Factor

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; CANCER PROCOAGULANT; MONOCLONAL ANTIBODY; PHOSPHOLIPID; THROMBOPLASTIN; TRYPSIN INHIBITOR; CYSTEINE PROTEINASE; THROMBIN; TUMOR PROTEIN;

ARTICLE; BREAST CANCER CELL LINE; BXPC-3 CELL LINE; CELL ACTIVATION; CELL COUNT; CONTROLLED STUDY; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MCF-7 CELL LINE; PANCREATIC CANCER CELL LINE; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBIN GENERATION; THROMBINOSCOPE; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; BREAST TUMOR; COLON TUMOR; FEMALE; HCT 116 CELL LINE; HT-29 CELL LINE; IMMUNOLOGY; METABOLISM; OVARY TUMOR; PANCREAS TUMOR; THROMBOCYTE RICH PLASMA; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYSTEINE ENDOPEPTIDASES; FACTOR XII; FEMALE; HCT116 CELLS; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PLATELET-RICH PLASMA; THROMBIN; THROMBOPLASTIN;

EID: 85033441252     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2017.4172     Document Type: Article

References (38)

1. Trousseau A: Clinique Médicale de l'Hôtel-Dieu de Paris. Vol. 3, 2nd edition. JB Baillière, Paris, pp654-712, 1865.
2. Falanga A, Russo L and Milesi V: The coagulopathy of cancer. Curr Opin Hematol 21: 423-429, 2014.
3. Khorana AA, Francis CW, Culakova E, Kuderer NM and Lyman GH: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5: 632-634, 2007.
4. Chew HK, Wun T, Harvey D, Zhou H and White RH: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458-464, 2006.
5. Prandoni P, Falanga A and Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 6: 401-410, 2005.
6. Lee AY and Levine MN: Venous thromboembolism and cancer: Risks and outcomes. Circulation 107 (Suppl 1): I17-I21, 2003.
7. Caine GJ, Stonelake PS, Lip GY and Kehoe ST: The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia 4: 465-473, 2002.
8. De Cicco M: The prothrombotic state in cancer: Pathogenic mechanisms. Crit Rev Oncol Hematol 50: 187-196, 2004.
9. Roberts HR, Hoffman M and Monroe DM: A cell-based model of thrombin generation. Semin Thromb Hemost 32 (Suppl 1): 32-38, 2006.
10. Amin C, Mackman N and Key NS: Microparticles and cancer. Pathophysiol Haemost Thromb 36: 177-183, 2008.
11. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH and Francis JL: Tissue factor-bearing microparticles derived from tumor cells: Impact on coagulation activation. J Thromb Haemost 6: 1517-1524, 2008.
12. Rauch U and Nemerson Y: Circulating tissue factor and thrombosis. Curr Opin Hematol 7: 273-277, 2000.
13. Butenas S, Orfeo T and Mann KG: Tissue factor activity and function in blood coagulation. Thromb Res 122 (Suppl 1): S42-S46, 2008.
14. Mackman N: The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 108: 1447-1452, 2009.
15. Mutch NJ: Emerging roles for factor XII in vivo. J Thromb Haemost 9: 1355-1358, 2011.
16. Möller F and Renné T: Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 15: 516-521, 2008.
17. Thomassen MC, Heinzmann AC, Herfs L, Hartmann R, Dockal M, Scheiflinger F, Hackeng TM and Rosing J: Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α. J Thromb Haemost 13: 92-100, 2015.
18. Nickel KF, Ronquist G, Langer F, Labberton L, Fuchs TA, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou EX, et al: The polyphosphate-factor XII pathway drives coagulation in prostate cancer-Associated thrombosis. Blood 126: 1379-1389, 2015.
19. Gordon SG and Mielicki WP: Cancer procoagulant: A factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 8: 73-86, 1997.
20. Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N and Gordon SG: Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Res 46: 6471-6474, 1986.
21. Gerotziafas GT, Galea V, Mbemba E, Khaterchi A, Sassi M, Baccouche H, Prengel C, van Dreden P, Hatmi M, Bernaudin JF, et al: Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res 129: 779-786, 2012.
22. Marchetti M, Diani E, ten Cate H and Falanga A: Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica 97: 1173-1180, 2012.
23. Van Dreden P, Rousseau A, Savoure A, Lenormand B, Fontaine S and Vasse M: Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction. Blood Coagul Fibrinolysis 20: 635-641, 2009.
24. Rousseau A, Favier R and Van Dreden P: Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: New and useful markers for pre-eclampsia? Eur J Obstet Gynecol Reprod Biol 146: 46-49, 2009.
25. Schneider P, Van Dreden P, Rousseau A, Kassim Y, Legrand E , Vannier JP and Vasse M: Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia. Br J Haematol 148: 582-592, 2010.
26. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E , Wagenvoord R, Lecompte T and Béguin S: The calibrated automated thrombogram (CAT): A universal routine test for hyper-And hypocoagulability. Pathophysiol Haemost Thromb 32: 249-253, 2002.
27. Gerotziafas GT, Depasse F, Busson J, Leflem L, Elalamy I and Samama MM: Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 3: 16, 2005.
28. Tilley RE, Holscher T, Belani R, Nieva J and Mackman N: Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res 122: 604-609, 2008.
29. Key NS, Chantrathammachart P, Moody PW and Chang JY: Membrane microparticles in VTE and cancer. Thromb Res 125 (Suppl 2): S80-S83, 2010.
30. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer K A, Furie BC and Furie B: Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15: 6830-6840, 2009.
31. Bogdanov VY, Kirk RI, Miller C, Hathcock JJ, Vele S, Gazdoiu M, Nemerson Y and Taubman MB: Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 4: 158-167, 2006.
32. Böing AN, Hau CM, Sturk A and Nieuwland R: Human alternatively spliced tissue factor is not secreted and does not trigger coagulation. J Thromb Haemost 7: 1423-1426, 2009.
33. Szotowski B, Antoniak S and Rauch U: Alternatively spliced tissue factor: A previously unknown piece in the puzzle of hemostasis. Trends Cardiovasc Med 16: 177-182, 2006.
34. Censarek P, Bobbe A, Grandoch M, Schrör K and Weber AA: Alternatively spliced human tissue factor (asHTF) is not procoagulant. Thromb Haemost 97: 11-14, 2007.
35. Spronk HM, Dielis AW, Panova-Noeva M, van Oerle R , Govers-Riemslag JW, Hamulyák K, Falanga A and Cate H T: Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed? Thromb Haemost 101: 1156-1162, 2009.
36. van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE and Makris M: Corn trypsin inhibitor in fluorogenic thrombingeneration measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis 19: 183-189, 2008.
37. Parhami-Seren B, Butenas S, Krudysz-Amblo J and Mann KG: Immunologic quantification of tissue factors. J Thromb Haemost 4: 1747-1755, 2006.
38. Berntorp E and Salvagno GL: Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 34: 670-682, 2008.